Full Dose Cyclophosphamide with the Addition of Fludarabine for Matched Sibling Transplants in Severe Aplastic Anemia

Fakih, Riad El; Ahmed, Syed Osman; Shaheen, Marwan; Chaudhri, Naeem; Alsharif, Fahad; Hanbali, Amr; Alfraih, Feras; Alshaibani, Alfadel; Assiri, Ali; Samarkandi, Hadeel; Babiker, Fatima; Alshomar, Ahmad; Alhakim, Anas; Ghabashi, Emad; Kotb, Ahmed; Elhassan, Tusneem; Balbaid, Ahmed; Alsadi, Husam; Rasheed, Walid; Al-Ahmari, Ali; Alzahrani, Hazzaa; Almohareb, Fahad; Aljurf, Mahmoud

doi:10.1016/j.jtct.2021.06.004

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, advances in medical science have resulted in innovative treatment strategies. Hematopoietic stem cell transplantation from a matched sibling donor has been considered the gold standard for treatment, offering a potential cure ( 8 , 9 ). However, the availability of suitable donors is limited, and the procedure carries risks of complications ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Unraveling trajectories from aplastic anemia to hematologic malignancies: genetic and molecular insights

Kim,

Choi,

Lee

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundAplastic anemia (AA), characterized by hematopoietic stem cell deficiency, can evolve into different hematologic malignancies. Our understanding of the genetic basis and mechanisms of this progression remains limited.MethodsWe retrospectively studied 9 acquired AA patients who later developed hematologic malignancies. Data encompassed clinical, laboratory, karyotype, and next-generation sequencing (NGS) information. We explored chromosomal alterations and mutation profiles to uncover genetic changes underlying the transition.ResultsNine AA patients developed myelodysplastic syndrome (seven patients), acute myeloid leukemia (one patient), or chronic myelomonocytic leukemia (one patient). Among eight patients with karyotype results at secondary malignancy diagnosis, monosomy 7 was detected in three. Trisomy 1, der(1;7), del(6q), trisomy 8, and del(12p) were detected in one patient each. Among three patients with NGS results at secondary malignancy diagnosis, KMT2C mutation was detected in two patients. Acquisition of a PTPN11 mutation was observed in one patient who underwent follow-up NGS testing during progression from chronic myelomonocytic leukemia to acute myeloid leukemia.ConclusionThis study highlights the genetic dynamics in the progression from AA to hematologic malignancy. Monosomy 7’s prevalence and the occurrence of PTPN11 mutations suggest predictive and prognostic significance. Clonal evolution underscores the complexity of disease progression.

show abstract

Section: Introductionmentioning

confidence: 99%